贝伐单抗治疗进展期非小细胞肺癌临床疗效及安全性观察

贝伐单抗是重组人源化血管内皮生长因子（vascular endothelial growth factor，VEGF）的IgG1型单克隆抗体，能与所有VEGF异构体结合，从而阻断VEGF与VEGFR结合，以抑制VEGF活性，是一种抑制血管生成的靶向治疗药物，联合化疗用于非鳞型非小细胞肺癌的一线治疗，可以延长无进展生存期及总生存期，提高有效率；2006年10月美国FDA推荐贝伐单抗联合紫杉醇/卡铂化疗方案用于非鳞型非小细胞肺癌的一线治疗。贝伐单抗治疗的安全性受到广泛关注，最常见的不良反应包括高血压、蛋白尿、血管栓塞、出血等，相关不良反应不容忽视，但高血压、蛋白尿、血管栓塞等可以通过对症处理得到控制，且与常规化疗药物不良反应不相互重叠，与化疗药物联合应用安全性较高，多数患者耐受性良好。本文就贝伐单抗治疗进展期非小细胞肺癌临床疗效及安全性进行综述。 

Assessment of the Efficacy and Safety of Avastin in Patients with Non-small Cell Lung Cancer

Avastin is a recombinant humanized monoclonal IgG1 antibody that selectively binds to and neutralizes the biological activity of human vascular endothelial growth factor ( VEGF ). It is the first targeted agent to increase efficacy in first-line non-small cell lung cancer (NSCLC) and was approved by the U.S. Food and Drug Administration in October 2006 for use in combination with carboplatin and paclitaxel for the initial treatment of patients with NSCLC. An improvement in the objective response and a trend toward better disease-free survival and overall survival rate were observed after Avastin administration. Adverse effects, such as hypertension, proteinuria, thromboembolism, and hemorrhage, were not severe and could be well tolerated. Most patients experienced few adverse effects. The present article reviews the efficacy and safety of Avastin in patients with NSCLC.